Australia markets closed
  • ALL ORDS

    7,562.50
    -37.40 (-0.49%)
     
  • AUD/USD

    0.7142
    +0.0014 (+0.19%)
     
  • ASX 200

    7,239.80
    -39.50 (-0.54%)
     
  • OIL

    71.64
    +3.49 (+5.12%)
     
  • GOLD

    1,795.70
    +7.60 (+0.43%)
     
  • BTC-AUD

    80,406.55
    +3,474.20 (+4.52%)
     
  • CMC Crypto 200

    1,435.93
    -19.48 (-1.34%)
     

Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?

·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting